Список литературы. 
Гломерулярные болезни почек

1. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics. Jun 2000;105(6):1242−9. [Medline].

2. International Study of Kidney Disease in Children (ISKDC). Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. Feb 1978;13(2):159−65. [Medline].

3. International Study of Kidney Disease in Children (ISKDC). The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. Apr 1981;98(4):561−4. [Medline].

4. van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond). Aug 2004;107(2):125−36. [Medline].

5. Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol. Apr 1996;10(2):171−4. [Medline].

6. Niaudet P. Genetic forms of nephrotic syndrome. Pediatr Nephrol. Dec 2004;19(12):1313−8. [Medline].

7. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. Mar 30 2006;354(13):1387−401. [Medline].

8. Coward RJ, Foster RR, Patton D, et al. Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol. Mar 2005;16(3):629−37. [Medline].

9. Anderson S, Komers R, Brenner BM. Renal and Systemic Manifestations of Glomerular Disease. In: Brenner BM. Brenner and Rector’s The Kidney. 8th ed. Philadelphia: Saunders Elsvier; 2008: chap 26.

10. Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr. Apr 2002;14(2):197−204. [Medline].

11. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118(3):397−407. [Medline].

12. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. Aug 23 2003;362(9384):629−39. [Medline].

13. Churg J, Habib R, White RH. Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet. Jun 20 1970;760(1):1299−302. [Medline].

14. Borges FF, Shiraichi L, da Silva MP, Nishimoto EI, Nogueira PC. Is focal segmental glomerulosclerosis increasing in patients with nephrotic syndrome?. Pediatr Nephrol. Sep 2007;22(9):1309−13. [Medline].

15. Boyer O, Moulder JK, Somers MJ. Focal and segmental glomerulosclerosis in children: a longitudinal assessment. Pediatr Nephrol. Aug 2007;22(8):1159−66. [Medline].

16. Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol. Jul 1991;5(4):393−7. [Medline].

17. Strife CF, Braun MC and West CD. Membranoproliferative Glomerulonephritis. In: Avner E, Harmon W and Niaudet P. Pediatric Nephrology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2004: chap 32.

18. Makker SP. Membranous Nephropathy. In: Avner E, Harmon W and Niaudet P. Pediatric Nephrology. 5thed. Philadelphia: Lippincott, Williams & Wilkins; 2004: chap 33.

19. Ekka BK, Bagga A, Srivastava RN. Singleversus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol. Oct 1997;11(5):597−9. [Medline].

20. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr. Apr 1993;152(4):357−61. [Medline].

21. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. Oct 17 2007;CD001533. [Medline].

22. [Best Evidence] Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. Jan 23 2008;CD002290. [Medline].

23. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. Mar 2001;16(3):271−82. [Medline].

24. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fьr Pдdiatrische Nephrologie (APN). Arch Dis Child. Nov 1987;62(11):1102−6. [Medline].

25. Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child. Oct 1990;65(10):1147−50. [Medline].

26. Takeuchi H, Matsuno N, Senuma K, et al. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter—why cyclosporine is monitored by C (2) level and tacrolimus by trough level—. Biol Pharm Bull. Jan 2008;31(1):90−4. [Medline].

27. Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant. Jul 2006;21(7):1848−54. [Medline].

28. [Best Evidence] Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. May 2009;53(5):760−9. [Medline].

29. [Best Evidence] Hodson EM, Habashy D, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. Apr 19 2006;CD003594. [Medline].

30. Del Rio M, Kaskel F. Evaluation and management of steroid-unresponsive nephrotic syndrome. Curr Opin Pediatr. Apr 2008;20(2):151−6. [Medline].

31. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol. Jul 1990;4(4):303−7. [Medline].

32. American Academy of Pediatrics. Immunization in Special Clinical Circumstances. In: Pickering LK, Baker CJ, Long SS, McMillan JA. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.

33. Alpay H, Yildiz N, Onar A, Temizer H, Ozcay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. Mar 2002;17(3):181−3. [Medline].

34. Report of the International Study of Kidney Disease in Children (RISKDC). Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. Report of the International Study of Kidney Disease in Children. Pediatrics. Apr 1984;73(4):497−501. [Medline].

35. Wu HM, Tang JL, Sha ZH, Cao L, Li YP. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev. 2004;CD003964. [Medline].

36. Zaffanello M, Franchini M. Thromboembolism in childhood nephrotic syndrome: a rare but serious complication. Hematology. Feb 2007;12(1):69−73. [Medline].

37. Citak A, Emre S, Sвirin A, Bilge I, Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. Feb 2000;14(2):138−42. [Medline].

38. Prescott WA Jr, Streetman DA, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother. Dec 2004;38(12):2105−14. [Medline].

39. Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr. Mar 1997;130(3):470−4. [Medline].

40. Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol. Dec 2003;18(12):1289−92. [Medline].

41. Tarshish P, Tobin JN, Bernstein J. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. May 1997;8(5):769−76. [Medline].

42. Ruth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. Aug 2005;147(2):202−7. [Medline].

43. Abeyagunawardena AS, Sebire NJ, Risdon RA, et al. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol. Feb 2007;22(2):215−21. [Medline].

44. Gipson DS, Chin H, Presler TP, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol. Mar 2006;21(3):344−9. [Medline].

45. Paik KH, Lee BH, Cho HY, et al. Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol. Mar 2007;22(3):389−95. [Medline].

46. Niaudet P. Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children. In: Avner E, Harmon W and Niaudet P. Pediatric Nephrology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2004: chap 27.

47. Niaudet P. Steroid-Resistant Idiopathic Nephrotic Syndrome in Children. In: Avner E, Harmon W, and Niaudet P. Pediatric Nephrology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2004: chap 28.

48. Zhao J, Cui Z, Yang R, et al. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int. Sep 9 2009;[Medline].

49. Yang R, Cui Z, Zhao J, et al. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin Immunol. Aug 3 2009;[Medline].

50. Yang R, Hellmark T, Zhao J, et al. Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. Nephrol Dial Transplant. Jun 2009;24(6):1838−44. [Medline].

51. Zhao J, Yan Y, Cui Z, et al. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity. Hum Immunol. Jun 2009;70(6):425−9. [Medline].

52. Bolton WK. Goodpasture''s syndrome. Kidney Int. Nov 1996;50(5):1753−66. [Medline].

53. Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture''s syndrome). Am J Ind Med. 1992;21(2):141−53. [Medline].

54. Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med. Sep 2004;25(3):583−92, vii.

55. Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. Dec 17 1983;2(8364):1390−3. [Medline].

56. Frankel SK, Cosgrove GP, Fischer A. Update in the diagnosis and management of pulmonary vasculitis. Chest. Feb 2006;129(2):452−65.

57. Jara LJ, Vera-Lastra O, Calleja MC. Pulmonary-renal vasculitic disorders: differential diagnosis and management. Curr Rheumatol Rep. Apr 2003;5(2):107−15. [Medline].

58. Jayne DR, Marshall PD, Jones SJ. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. Mar 1990;37(3):965−70. [Medline].

59. Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. Nov 1999;10(11):2446−53. [Medline].

60. Lockwood CM, Rees AJ, Pearson TA. Immunosuppression and plasma-exchange in the treatment of Goodpasture''s syndrome. Lancet. Apr 3 1976;1(7962):711−5. [Medline].

61. Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol. Mar 1996;7(3):367−86. [Medline].

62. Mehler PS, Brunvand MW, Hutt MP. Chronic recurrent Goodpasture''s syndrome. Am J Med. Apr 1987;82(4):833−5. [Medline].

63. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. Jun 1994;23(6):817−27. [Medline].

64. Rutgers A, Slot M, van Paassen P. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. Aug 2005;46(2):253−62.

65. Savage CO, Pusey CD, Bowman C. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980;4. Br Med J (Clin Res Ed). Feb 1 1986;292(6516):301−4. [Medline].

66. Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture''s syndrome. South Med J. Dec 2002;95(12):1411−8. [Medline].

67. Sinico RA, Radice A, Corace C. Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. Nephrol Dial Transplant. Feb 2006;21(2):397−401.

68. Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion. Feb 1989;29(2):124−7. [Medline].

69. Weber MF, Andrassy K, Pullig O. Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture''s syndrome and in Wegener''s granulomatosis. J Am Soc Nephrol. Jan 1992;2(7):1227−34. [Medline].

70. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). Jan 1999;78(1):26−37. [Medline].

71. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. Mar-Apr 1951;27(2):277−301. [Medline].

72. Churg A. Pulmonary angiitis and granulomatosis revisited. Hum Pathol. Oct 1983;14(10):868−83. [Medline].

73. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. Sep 2003;115(4):284−90. [Medline].

74. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. Aug 1990;33(8):1094−100. [Medline].

75. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. Feb 1994;37(2):187−92. [Medline].

76. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. Nov-Dec 2003;21(6 Suppl 32):S69−77. [Medline].

77. Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. Thorax. Jun 1999;54(6):558−60. [Medline].

78. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. Mar 2000;117(3):708−13. [Medline].

79. Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. Aug 2008;63(8):677−82. [Medline].

80. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. Feb 11 1998;279(6):455−7. [Medline].

81. Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. Sep 2007;56(9):3159−66. [Medline].

82. Eustace JA, Nadasdy T, Choi M. Disease of the month. The Churg Strauss Syndrome. J Am Soc Nephrol. Sep 1999;10(9):2048;55. [Medline].

83. Hasley PB, Follansbee WP, Coulehan JL. Cardiac manifestations of Churg-Strauss syndrome: report of a case and review of the literature. Am Heart J. Oct 1990;120(4):996−9. [Medline].

84. Keogh KA, Specks U. Churg-Strauss syndrome: update on clinical, laboratory and therapeutic aspects. Sarcoidosis Vasc Diffuse Lung Dis. Mar 2006;23(1):3−12. [Medline].

85. Sinico RA, Sabadini E, Maresca AM. Mesalazine-induced Churg-Strauss syndrome in a patient with Crohn’s disease and sclerosing cholangitis. Clin Exp Rheumatol. Mar-Apr 2006;24(2 Suppl 41):S104. [Medline].

86. Orriols R, Muсoz X, Ferrer J, Huget P, Morell F. Cocaine-induced Churg-Strauss vasculitis. Eur Respir J. Jan 1996;9(1):175−7. [Medline].

87. Sablй-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. Nov 1 2005;143(9):632−8. [Medline].

88. Choi YH, Im JG, Han BK, Kim JH, Lee KY, Myoung NH. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest. Jan 2000;117(1):117−24. [Medline].

89. Kim Y, Lee KS, Choi DC, et al. The spectrum of eosinophilic lung disease: radiologic findings. J Comput Assist Tomogr. Nov-Dec 1997;21(6):920−30. [Medline].

90. Buschman DL, Waldron JA Jr, King TE Jr. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis. Aug 1990;142(2):458−61. [Medline].

91. Worthy SA, Mьller NL, Hansell DM, Flower CD. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR Am J Roentgenol. Feb 1998;170(2):297−300. [Medline].

92. Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am. Nov 1995;21(4):883−909. [Medline].

93. Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung. A review. Am J Clin Pathol. Nov 2000;114(5):767−72. [Medline].

94. Chemmalakuzhy AJ, Zhou XJ, Hedayati SS. ANCA-negative glomerulonephritis associated with nonasthmatic Churg-Strauss syndrome. Nat Clin Pract Nephrol. Oct 2008;4(10):568−74. [Medline].

95. Lhote F, Cohen P, Guilpain P, Guillevin L. [Churg-Strauss syndrome]. Rev Prat. Jun 15 2008;58(11):1165−74. [Medline].

96. Grau RG. Churg-Strauss syndrome: 2005;2008 update. Curr Rheumatol Rep. Dec 2008;10(6):453−8. [Medline].

97. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. Jul 2008;67(7):1004−10. [Medline].

98. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther. 2005;7(5):R1072−81. [Medline].

99. Cohen P, Guillevin L, Baril L, et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol. Mar-Apr 1995;13(2):193−8. [Medline].

100. Espinoza LR. Combination therapy to treat churg-strauss syndrome: corticosteroids with shortor long-term cyclophosphamide pulses. Curr Rheumatol Rep. Dec 2008;10(6):427−9. [Medline].

101. Yamasaki A, Tomita K, Fujii Y, Hasegawa Y, Watanabe M, Sano H, et al. Repressed ileal artery aneurysms in Churg-Strauss syndrome following combination treatment with glucocorticoid and cyclophosphamide. Rheumatol Int. Aug 8 2008;[Medline].

102. Ribi C, Cohen P, Pagnoux C, Mahr A, Arиne JP, Lauque D, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. Feb 2008;58(2):586−94. [Medline].

103. Guillevin L, Cevallos R, Durand-Gasselin B, et al. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris). 1997;148(3):198−204. [Medline].

104. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. Sep 1 1998;129(5):370−4. [Medline].

105. Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol. May-Jun 2008;26(3 Suppl 49):S35−40. [Medline].

106. Beasley R, Bibby S, Weatherall M. Leukotriene receptor antagonist therapy and Churg-Strauss syndrome: culprit or innocent bystander?. Thorax. Oct 2008;63(10):847−9. [Medline].

107. Boyer D, Vargas SO, Slattery D, Rivera-Sanchez YM, Colin AA. Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics. Sep 2006;118(3):e914−20. [Medline].

108. Chumbley LC, Harrison EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc. Aug 1977;52(8):477−84. [Medline].

109. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Omalizumab and Churg-Strauss syndrome. J Allergy Clin Immunol. Jul 2008;122(1):217; author reply 217−8. [Medline].

110. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol. May 2007;119(5):1279; author reply 1279−80. [Medline].

111. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet. Feb 27 1999;353(9154):725−6. [Medline].

112. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). Jan 1999;78(1):26−37. [Medline].

113. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). Jan 1996;75(1):17−28. [Medline].

114. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. Aug 2006;65(8):1116−7. [Medline].

115. Kьmpers P, Erdbrьgger U, Grossheim M, Meyer GP, Hiss M, Gwinner W, et al. Endothelial microparticles as a diagnostic aid in Churg-Strauss vasculitis-induced cardiomyopathy. Clin Exp Rheumatol. May-Jun 2008;26(3 Suppl 49):S86−9. [Medline].

116. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). Mar 1984;63(2):65−81. [Medline].

117. Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am. Nov 1995;21(4):911−47. [Medline].

118. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum. Aug 1990;33(8):1074−87. [Medline].

119. Lightfoot RW Jr. Churg-Strauss syndrome and polyarteritis nodosa. Curr Opin Rheumatol. Feb 1991;3(1):3−7. [Medline].

120. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet. Feb 15 2003;361(9357):587−94. [Medline].

121. Pabst S, Tiyerili V, Grohй C. Apparent response to anti-IgE therapy in two patients with refractory «forme fruste» of Churg-Strauss syndrome. Thorax. Aug 2008;63(8):747−8. [Medline].

122. Roccatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol. May-Jun 2008;26(3 Suppl 49):S67−71. [Medline].

123. Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum. Mar 1998;41(3):445−52. [Medline].

124. Specks U, DeRemee RA. Granulomatous vasculitis. Wegener’s granulomatosis and Churg-Strauss syndrome. Rheum Dis Clin North Am. May 1990;16(2):377−97. [Medline].

125. Tidman M, Olander R, Svalander C, Danielsson D. Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975;95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med. Aug 1998;244(2):133−41. [Medline].

126. Tiliakos A 4th, Shaia S, Hostoffer R, Kent L. The use of infliximab in a patient with steroid-dependent churg-strauss syndrome. J Clin Rheumatol. Apr 2004;10(2):96−7. [Medline].

127. Todd DC, Cockcroft DW. Prolonged survival in Churg-Strauss syndrome. Ann Allergy Asthma Immunol. Jan 2004;92(1):92−3. [Medline].

128. Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax. Sep 2000;55(9):805−6. [Medline].

129. Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. Mar 2000;117(3):708−13. [Medline].

130. Weyand CM, Goronzy JJ. Multisystem interactions in the pathogenesis of vasculitis. Curr Opin Rheumatol. Jan 1997;9(1):3−11. [Medline].

131. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med. Sep 21 2006;355(12):1281−2. [Medline].

132. Kussmaul A, Maier R. Ueber eine bisher nicht beschriebene eigenthьmliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellдhmung einhergeht. Dtsch Arch Klin Med. 1866;1:484−518.

133. Stone JH. Polyarteritis nodosa. JAMA. Oct 2 2002;288(13):1632−9. [Medline].

134. Colmegna I, Maldonado-Cocco JA. Polyarteritis nodosa revisited. Curr Rheumatol Rep. Aug 2005;7(4):288−96. [Medline].

135. Matteson EL. A history of early investigation in polyarteritis nodosa. Arthritis Care Res. Aug 1999;12(4):294−302. [Medline].

136. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. Q J Med. Jul 1948;17(67):175−202. [Medline].

137. Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. Aug 1990;33(8):1088−93. [Medline].

138. Jennette JC, Falk RJ, Andrassy K. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. Feb 1994;37(2):187−92. [Medline].

139. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun. May 2001;16(3):269−74. [Medline].

140. McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP. Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up. Hepatology. Jan 1989;9(1):97−101. [Medline].

141. Mahr A, Guillevin L, Poissonnet M, Aymй S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. Feb 15 2004;51(1):92−9. [Medline].

142. Selga D, Mohammad A, Sturfelt G, Segelmark M. Polyarteritis nodosa when applying the Chapel Hill nomenclature—a descriptive study on ten patients. Rheumatology (Oxford). Oct 2006;45(10):1276−81. [Medline].

143. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. Jul 1967;43(1):8−14. [Medline].

144. Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986;2000): presentation and outcomes in 24 patients. Am J Med. Apr 1 2002;112(5):386−91. [Medline].

145. Fernandes SR, Coimbra IB, Costallat LT. Uncommon features of polyarteritis nodosa: psychosis and angio-oedema. Clin Rheumatol. 1998;17(4):353−6. [Medline].

146. Griffin JW. Vasculitic neuropathies. Rheum Dis Clin North Am. Nov 2001;27(4):751−60, vi. [Medline].

147. Watts RA, Mooney J, Lane SE, Scott DG. Rheumatoid vasculitis: becoming extinct?. Rheumatology (Oxford). Jul 2004;43(7):920−3. [Medline].

148. Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. Oct 1995;25(2):134−42. [Medline].

149. Hughes LB, Bridges SL Jr. Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations. Curr Rheumatol Rep. Feb 2002;4(1):75−82. [Medline].

150. Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis. Apr 1995;20(4):1010−36. [Medline].

151. Soufir N, Descamps V, Crickx B. Hepatitis C virus infection in cutaneous polyarteritis nodosa: a retrospective study of 16 cases. Arch Dermatol. Aug 1999;135(8):1001−2. [Medline].

152. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore). Sep 1995;74(5):238−53. [Medline].

153. Ricotti C, Kowalczyk JP, Ghersi M, Nousari CH. The diagnostic yield of histopathologic sampling techniques in PAN-associated cutaneous ulcers. Arch Dermatol. Oct 2007;143(10):1334−6. [Medline].

154. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). Jan 1996;75(1):17−28. [Medline].

155. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. Mar 2001;44(3):666−75. [Medline].

156. Guillevin L, Mahr A, Cohen P, Larroche C, Queyrel V, Loustaud-Ratti V, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum. Jun 15 2004;51(3):482−7. [Medline].

157. Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol. Feb 1993;20(2):289−98. [Medline].

158. Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis. May 1994;53(5):334−7. [Medline].

159. Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Hдussinger D. Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine. J Hepatol. Oct 2000;33(4):677−83. [Medline].

160. Wicki J, Olivieri J, Pizzolato G, Sarasin F, Guillevin L, Dayer JM. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford). Feb 1999;38(2):183−5. [Medline].

161. Molloy PJ, Friedlander L, Van Thiel DH. Combined interferon, famciclovir and GM-CSF treatment of HBV infection in an individual with periarteritis nodosa. Hepatogastroenterology. Jul-Aug 1999;46(28):2529−31. [Medline].

162. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. Mar 15 1992;116(6):488−98. [Medline].

163. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Limited versus severe Wegener’s granulomatosis: baseline patient data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. August 2003;48(8):2299−2309. [Medline].

164. Kallenberg CGM. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun. February-March 2008;30:29−36. [Medline].

165. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener’s Granulomatosis. Am J Med. July 2007;120:643.e9−14. [Medline].

166. Kallenberg CGM, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitis. Nat Clin Pract Rheumatol. December 2006;2:661−670. [Medline].

167. Moosig F, Lamprecht P, Gross WL. Wegener’s Granulomatosis: the current view. Clin Rev Allergy Immunol. October 2008;35(1−2):19−21. [Medline].

168. Spagnolo P, Richeldi L, DuBois RM. Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. Semin Respir Crit Care Med. December 2008;29:610−619. [Medline].

169. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. January 1994;120(1):12−17. [Medline].

170. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. September-October 2008;26:S94-S104. [Medline].

171. Watts RA, Lane SE, Koldingsnes W, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. December 2001;60(12):1156−7. [Medline].

172. Fauci AS, Haynes BS, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. January 1983;98(1):76−85. [Medline].

173. Manganelli P, Fietta P, Carotti M, Pesci A, Salaffi F. Respiratory system involvement in systemic vasculitis. Clin Exp Rheumatol. March-April 2006;24:S48-S59. [Medline].

174. Hinze CH, Colbert RA. B-cell depletion in Wegener’s Granulomatosis. Clin Rev Allergy Immunol. June 2008;34:372−379. [Medline].

175. Al-Hakeem DA, Fedele S, Carlos R, Porter S. Extranodal NK/T-cell lymphoma, nasal type. Oral Oncol. January 2007;43(1):4−14. [Medline].

176. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. August 1990;33(8):1101−1107. [Medline].

177. Renaudineau Y, Le Meur Y. Renal involvement in Wegener’s Granulomatosis. Clinic Rev Allerg Immunol. October 2008;35:22−29. [Medline].

178. Polychronopoulos VS, Prakash UBS, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener’s Granulomatosis. Rheum Dis Clin N Am. November 2007;33:755−775. [Medline].

179. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. March 2009;68:310−317. [Medline].

180. Frankel SK, Cosgrove GP, Fischer A. Update in the diagnosis and management of pulmonary vasculitis. Chest. February 2006;129(2):452−65. [Medline].

181. DeGroot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. May 2009;150:670−680. [Medline].

182. [Best Evidence] DeGroot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. August 2005;52:2461−2469. [Medline].

183. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. October 1991;40(4):757−763. [Medline].

184. [Best Evidence] Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. July 2007;18(7):2180−2188. [Medline].

185. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. December 2003;42(6):1149−1153. [Medline].

186. Jayne D, Rasmussen N, Andrassey K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic antibodies. N Engl J Med. July 2003;349(1):36−44. [Medline].

187. Sanders JS, Slot MC, Stegeman CA. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. November 2003;349(21):2072;2073. [Medline].

188. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. April 2004;51(2):269−273. [Medline].

189. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. December 2008;359:2790−2803. [Medline].

190. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford). July 2007;46(7):1087−1091. [Medline].

191. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. Jul 4 1996;335(1):16−20. [Medline].

192. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: a systematic review. JAMA. August 2007;298:655−669. [Medline].

193. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. January 2008;58(1):308−371. [Medline].

194. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. December 2005;20(12):2725−2732. [Medline].

195. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract. 2006;102(3−4):c100−7. [Medline].

196. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. May 2001;44(5):1149−1154. [Medline].

197. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s Granulomatosis. N Engl J Med. Jan 27 2005;352(4):351−61. [Medline].

198. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. Mar 2004;15(3):717−21. [Medline].

199. Lee RW, D’Cruz DP. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs. 2008;68:747−770. [Medline].

200. Sangle SR, Hughes GR, D’Cruz DP. Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects. Ann Rheum Dis. April 2007;66(4):564−565. [Medline].

201. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). November 2006;45(11):1432−1436. [Medline].

202. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. January 2006;173(2):180−187. [Medline].

203. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. July 2006;65(7):853−858. [Medline].

204. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol. October 2008;35(10):2017;2023. [Medline].

205. Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol. February 2003;14(2):440−447. [Medline].

206. Schmitt WH, Birck R, Heinzel PA, et al. Prolonged treatment of refractory Wegener’s granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant. June 2005;20(6):1083−1092. [Medline].

207. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. April 2004;65(4):1440−1448. [Medline].

208. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. September 2008;67(9):1322−1327. [Medline].

209. Seo P, Min Y-I, Holbrook JT, et al. Damage caused by Wegener’s Granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. July 2005;52:2168−2178. [Medline].

210. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. July 2008;67:1004−1010. [Medline].

211. Haroun MK, Stone JH, Nair R, Racusen L, Hellmann DB, Eustace JA. Correlation of percentage of normal glomeruli with renal outcome in Wegener’s granulomatosis. Am J Nephrol. September-December 2002;22(5−6):497−503. [Medline].

212. Hauer HA, Bajema IM, Van Houwelingen HC, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. November 2002;62(5):1732−1742. [Medline].

213. Brusselle CG. Pulmonary-renal syndromes. Acta Clin Belg. March-April 2007;62:88−96. [Medline].

214. Danda D, Mathew AJ, Mathew J. Wegener’s granulomatosis — a rare presentation. Clin Rheumatol. February 2008;27:273−275. [Medline].

215. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener’s granulomatosis. Curr Opin Rheumatol. Jan 2006;18(1):25−32. [Medline].

216. Jayne D. Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology (Carlton). February 2009;14(1):42−48. [Medline].

217. Lane SE, Watts R, Scott DGI. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. August 2005;7:270−275. [Medline].

218. Ponniah I, Shaheen A, Shankar KA, Kumaran MG. Wegener’s granulomatosis: the current understanding. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Sep 2005;100(3):265−70. [Medline].

219. Seo P. Wegener’s granulomatosis: managing more than inflammation. Curr Opin Rheum. January 2008;20:10−16. [Medline].

220. Stone JH, Hoffman GS. Wegener’s granulomatosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. Vol 2. 4th ed. Philadelphia, PA: Mosby Elsevier; 2008:1533−1544/Chap 146.

221. Watts RA, Scott DGI. Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol. May 1997;11(2):191−217. [Medline].

222. Weeda LW, Coffey SA. Wegener’s Granulomatosis. Oral Maxillofac Surg Clin North Am. November 2008;20:643−649. [Medline].

223. Kashtan CE. Familial hematuria. Pediatr Nephrol. Oct 2007;[Medline].

224. Gross O. Understanding renal disorders as systemic diseases: the fascinating world of basement membranes beyond the glomerulus. Nephrol Dial Transplant. Jun 2008;23(6):1823−5. [Medline].

225. Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol. Jan 2008;4(1):24−37. [Medline].

226. Meloni I, Vitelli F, Pucci L, et al. Alport syndrome and mental retardation: clinical and genetic dissection of the contiguous gene deletion syndrome in Xq22.3 (ATS-MR). J Med Genet. May 2002;39(5):359−65. [Medline].

227. United States Renal Data System. Annual Data Report 2008. USRDS — ADR. Available athttp://www.usrds.org/adr.htm. Accessed September 20, 2008.

228. Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a «European Community Alport Syndrome Concerted Action» study. J Am Soc Nephrol. Oct 2003;14(10):2603−10. [Medline].

229. Patey-Mariaud de Serre N, Garfa M, Bessieres B, Noel LH, Knebelmann B. Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients. Kidney Int. Aug 2007;72(4):512−6. [Medline].

230. Gubler MC. Diagnosis of Alport Syndrome without biopsy?. Pediatr Nephrol. May/2007;22:621−5. [Medline].

231. Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. Jan 2007;22(1):57−63. [Medline].

232. Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant. Sept 2006;10:651−7. [Medline].

233. Mojahedi MJ, Hekmat R, Ahmadnia H. Kidney transplantation in patients with alport syndrome. Urol J. Fall 2007;4(4):234−7. [Medline].

234. Callis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport’s syndrome. Kidney Int. Mar 1999;55(3):1051−6. [Medline].

235. Anker MC, Arnemann J, Neumann K, et al. Alport syndrome with diffuse leiomyomatosis. Am J Med Genet A. Jun 15 2003;119(3):381−5. [Medline].

236. Cohen EP, Lemann J Jr. In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression. Am J Kidney Dis. Feb 1996;27(2):199−203. [Medline].

237. Copelovitch L, Kaplan BS. Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical?. Pediatr Nephrol. Apr 2006;21(4):455−6. [Medline].

238. Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol. Aug 2005;130(4):620−7. [Medline].

239. Ghiggeri GM, Caridi G, Magrini U, et al. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis. Jan 2003;41(1):95−104. [Medline].

240. Gregory MC. Alport syndrome and thin basement membrane nephropathy: unraveling the tangled strands of type IV collagen. Kidney Int. Mar 2004;65(3):1109−10. [Medline].

241. Gubler MC, Knebelmann B, Antignac C, et al. Inherited glomerular disease. In: Inherited glomerular disease. Pediatric Nephrology. 4th Edition. Williams & Wilkins; 1999:475−95.

242. Heidet L, Arrondel C, Forestier L. Structure of the human type iv collagen gene col4a3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol. Jan 2001;12(1):97−106. [Medline].

243. Hu A, Wang F, Sellers JR. Mutations in human nonmuscle myosin IIA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function. J Biol Chem. Nov 29 2002;277(48):46 512−7. [Medline].

244. Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol. Oct 2004;15(10):2514−27. [Medline].

245. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med. Jun 19 2003;348(25):2543−56. [Medline].

246. Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotypephenotype correlations in males. J Am Soc Nephrol. Apr 2000;11(4):649−57. [Medline].

247. Kashtan CE. Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr. Apr 2004;16(2):177−81. [Medline].

248. Kashtan CE. Familial hematurias: what we know and what we don’t. Pediatr Nephrol. Aug 2005;20(8):1027−35. [Medline].

249. Longo I, Porcedda P, Mari F, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int. Jun 2002;61(6):1947;56. [Medline].

250. Longo I, Scala E, Mari F, et al. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant. Mar 2006;21(3):665−71. [Medline].

251. Martin P, Heiskari N, Zhou J, et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol. Dec 1998;9(12):2291−301. [Medline].

252. Mazzucco G, Barsotti P, Muda AO, et al. Ultrastructural and immunohistochemical findings in Alport’s syndrome: a study of 108 patients from 97 Italian families with particular emphasis on COL4A5 gene mutation correlations. J Am Soc Nephrol. Jun 1998;9(6):1023−31. [Medline].

253. Meloni I, Muscettola M, Raynaud M, et al. FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation. Nat Genet. Apr 2002;30(4):436−40. [Medline].

254. Nagel M, Nagorka S, Gross O. Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome. Hum Mutat. Jul 2005;26(1):60. [Medline].

255. Pescucci C, Mari F, Longo I, et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int. May 2004;65(5):1598−603. [Medline].

256. Pirson Y. Making the diagnosis of Alport’s syndrome. Kidney Int. Aug 1999;56(2):760−75. [Medline].

257. Proesmans W, Van Dyck M. Enalapril in children with Alport syndrome. Pediatr Nephrol. Mar 2004;19(3):271−5. [Medline].

258. Slajpah M, Meglic A, Furlan P, Glavac D. The importance of non-invasive genetic analysis in the initial diagnostics of Alport syndrome in young patients. Pediatr Nephrol. Sep 2005;20(9):1260−4. [Medline].

259. Takemura T, Yanagida H, Yagi K, et al. Alport syndrome and benign familial hematuria (thin basement membranedisease) in two brothers of a family with hematuria. Clin Nephrol. Sep 2003;60(3):195−200. [Medline].

260. Toren A, Rozenfeld-Granot G, Rocca B. Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11−13. Blood. Nov 15 2000;96(10):3447−51. [Medline].

261. Wang F, Wang Y, Ding J, Yang J. Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts. Kidney Int. Apr 2005;67(4):1268−74. [Medline].

262. White RH, Raafat F, Milford DV, et al. The Alport nephropathy: clinicopathological correlations. Pediatr Nephrol. Jul 2005;20(7):897−903. [Medline].

263. Yachnin T, Iaina A, Schwartz D, Nakache R. The mother of an Alport’s syndrome patient: a safe kidney donor?. Nephrol Dial Transplant. Apr 2002;17(4):683−4. [Medline].